Galasso 2021.

Study characteristics
Methods	Study design: randomised controlled trial Type of publication: preprint Setting and dates: online, December 2, 2020 ‐ December 10, 2020 Country: Australia, France, Germany, Italy, New Zealand, Poland, Sweden, UK, USA Language: NR
Interventions	Framing/Information provision Group 1: vaccine reduces infection Group 2: vaccine reduces contagion Group 3: vaccine helps your country Group 4: vaccine helps the economy Group 5: no additional vaccine information
Population	Population: adults in the participating countries Age; range: 18‐ 60+ Gender: Male, Female Ethnicity: NR Number of participants (recruited/allocated/evaluated): 13,326 assessed Inclusion/exclusion criteria: aged 18 years or above
Outcomes	Belief that the vaccine represents a permanent solution to the pandemic Agreement to be vaccinated Agreement to compulsory vaccination
Notes	COI: NR Funding: ANR (French Agency for Research)